SunTrust Banks Weighs in on AnaptysBio, Inc.’s FY2017 Earnings (ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB) – Stock analysts at SunTrust Banks issued their FY2017 earnings estimates for AnaptysBio in a research report issued on Wednesday. SunTrust Banks analyst Y. Suneja forecasts that the biotechnology company will post earnings of ($1.69) per share for the year. SunTrust Banks has a “Buy” rating and a $115.00 price objective on the stock. SunTrust Banks also issued estimates for AnaptysBio’s Q4 2017 earnings at ($0.44) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.64) EPS, Q3 2018 earnings at ($0.72) EPS, Q4 2018 earnings at ($0.80) EPS, FY2018 earnings at ($2.68) EPS, FY2019 earnings at ($3.65) EPS, FY2020 earnings at ($4.45) EPS and FY2021 earnings at ($4.65) EPS.

AnaptysBio (NASDAQ:ANAB) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.45) EPS for the quarter, topping analysts’ consensus estimates of ($0.47) by $0.02. COPYRIGHT VIOLATION WARNING: “SunTrust Banks Weighs in on AnaptysBio, Inc.’s FY2017 Earnings (ANAB)” was originally published by Community Financial News and is owned by of Community Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.com-unik.info/2017/11/18/suntrust-banks-weighs-in-on-anaptysbio-inc-s-fy2017-earnings-anab.html.

ANAB has been the topic of a number of other reports. Credit Suisse Group boosted their price target on shares of AnaptysBio from $34.00 to $38.00 and gave the company an “outperform” rating in a research note on Friday, August 25th. Zacks Investment Research raised shares of AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price target on the stock in a research note on Friday, November 10th. Royal Bank Of Canada boosted their price target on shares of AnaptysBio from $40.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. JMP Securities boosted their price target on shares of AnaptysBio from $45.00 to $82.00 and gave the company an “outperform” rating in a research note on Tuesday, October 10th. Finally, Robert W. Baird set a $69.00 price target on shares of AnaptysBio and gave the company a “buy” rating in a research note on Wednesday, October 11th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $84.78.

Shares of AnaptysBio (NASDAQ ANAB) opened at $76.64 on Friday. AnaptysBio has a 52 week low of $15.17 and a 52 week high of $79.18. The company has a current ratio of 10.77, a quick ratio of 10.77 and a debt-to-equity ratio of 0.09.

A number of hedge funds and other institutional investors have recently bought and sold shares of ANAB. Bank of New York Mellon Corp acquired a new position in AnaptysBio during the 1st quarter worth approximately $373,000. TIAA CREF Investment Management LLC acquired a new position in AnaptysBio during the 1st quarter worth approximately $227,000. Geode Capital Management LLC acquired a new position in AnaptysBio during the 1st quarter worth approximately $1,522,000. Bank of America Corp DE acquired a new position in AnaptysBio during the 1st quarter worth approximately $123,000. Finally, Spark Investment Management LLC grew its holdings in AnaptysBio by 113.5% during the 2nd quarter. Spark Investment Management LLC now owns 74,100 shares of the biotechnology company’s stock worth $1,773,000 after acquiring an additional 39,400 shares in the last quarter. Institutional investors own 59.04% of the company’s stock.

In other AnaptysBio news, major shareholder Holdings A/S Novo sold 356,300 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The shares were sold at an average price of $21.10, for a total transaction of $7,517,930.00. Following the completion of the transaction, the insider now owns 1,936,604 shares in the company, valued at approximately $40,862,344.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

What are top analysts saying about AnaptysBio Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for AnaptysBio Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit